BioCryst Pharmaceuticals Inc (BCRX) is a publicly traded Healthcare sector company. As of May 21, 2026, BCRX trades at $8.80 with a market cap of $2.28B and a P/E ratio of -5.07. BCRX moved -0.34% today. Year to date, BCRX is +17.95%; over the trailing twelve months it is -15.39%. Its 52-week range spans $6.00 to $11.31. Analyst consensus is strong buy with an average price target of $22.43. Rallies surfaces BCRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded BCRX stock?
Recent politician trading activity in BCRX includes disclosures from Gilbert Cisneros. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
BCRX Key Metrics
Key financial metrics for BCRX
Metric
Value
Price
$8.80
Market Cap
$2.28B
P/E Ratio
-5.07
EPS
$-1.73
Dividend Yield
0.00%
52-Week High
$11.31
52-Week Low
$6.00
Volume
205
Avg Volume
0
Revenue (TTM)
$885.72M
Net Income
$-457.98M
Gross Margin
97.75%
Congressional Trades in BCRX
Gilbert Cisneros purchase BCRX on Nov 13, 2025 (amount: $15.00K).
Recent politician trading activity in BCRX includes disclosures from Gilbert Cisneros. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in BCRX?
Yes. Rallies tracks politician and congressional stock disclosures for BCRX, including reported purchases, sales, dates, owners, and trade amounts when available.
Is BCRX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for BCRX. It does not provide personalized investment advice.
